Aptorum Group Ltd. Files 6-K with Interim Financials

TL;DR

Aptorum Group Ltd. just dropped its H1 2025 financials in a 6-K filing.

AI Summary

Aptorum Group Ltd. is filing a Form 6-K on October 3, 2025, to provide its six-month interim consolidated financial statements for the period ended June 30, 2025. This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Why It Matters

This filing provides investors with updated financial performance data for Aptorum Group Ltd. for the first half of 2025, allowing for assessment of the company's financial health and operational progress.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not contain new material events or significant financial changes.

Key Players & Entities

• Aptorum Group Ltd (company) — Filer of the report
• June 30, 2025 (date) — End date of the interim financial statements
• October 3, 2025 (date) — Filing date of the report
• 17 Hanover Square London W1S 1BN, United Kingdom (address) — Principal executive office address

FAQ

Filing Documents

• ea0256362-6k_aptorum.htm (6-K) — 21KB
• ea025636201ex99-1_aptorum.htm (EX-99.1) — 430KB
• ea025636201ex99-2_aptorum.htm (EX-99.2) — 104KB
• 0001213900-25-096129.txt ( ) — 3865KB
• apm-20250630.xsd (EX-101.SCH) — 42KB
• apm-20250630_cal.xml (EX-101.CAL) — 33KB
• apm-20250630_def.xml (EX-101.DEF) — 185KB
• apm-20250630_lab.xml (EX-101.LAB) — 345KB
• apm-20250630_pre.xml (EX-101.PRE) — 208KB
• ea0256362-6k_aptorum_htm.xml (XML) — 416KB

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibits . The following exhibits are attached. Exhibit Description 10.1 Merger Agreement by and between Aptorum and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025) 10.2 Management Services Agreement by and between Aptorum Therapeutics and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025) 10.3 Intellectual Property License Agreement by and between Aptorum Therapeutics, Aptorum, DiamiR LLC, and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025) 10.4 Voting and Support Agreement by and between Aptorum and its major shareholder, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025) 10.5 Form of Stockholders Agreement (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025) 99.1 Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and December 31, 2024, and for the Six Months Ended June 30, 2025 and 2024 99.2 Operating and Financial Review and Prospects in Connection with the Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2025 and 2024 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 3, 2025 Aptorum Group Limited By: /s/ Ian Huen Ian Huen Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR